GeneTx and Ultragenyx (RARE) Announce Positive Interim Phase 1/2 Data on Investigational GTX-102 Demonstrating Improvement in Patients with Angelman Syndrome

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 7/7/2026

1. SPCX
2. CRNX
3. VRTX
4. WMT
5. LMT
6. RXST
7. RIVN
8. SPGI
9. AGIO
10. NCNO

Go back to GeneTx and Ultragenyx (RARE) Announce Positive Interim Phase 1/2 Data on Investigational GTX-102 Demonstrating Improvement in Patients with Angelman Syndrome

Ultragenyx Pharma (RARE) Tops Q3 EPS by 14c, Revenues Beat

October 27, 2020 4:45 PM EDT

Ultragenyx Pharma (NASDAQ: RARE) reported Q3 EPS of ($1.13), $0.14 better than the analyst estimate of ($1.27). Revenue for the quarter came in at $81.5 million versus the consensus estimate of $53.89 million.

Third quarter 2020 total revenue of $81.5 million and Crysvita revenue of $37.3 millionIncreased lower end of... More